Senseonics Holdings, Inc. Stock

Equities

SENS

US81727U1051

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 16:00:00 2024-04-29 EDT 5-day change 1st Jan Change
0.436 USD +4.88% Intraday chart for Senseonics Holdings, Inc. +9.33% -23.52%
Sales 2024 * 26.06M 35.66M Sales 2025 * 38.91M 53.24M Capitalization 231M 317M
Net income 2024 * -78M -107M Net income 2025 * -70M -95.77M EV / Sales 2024 * 8.88 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 5.95 x
P/E ratio 2024 *
-3.49 x
P/E ratio 2025 *
-3.88 x
Employees 132
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.91%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.88%
1 week+9.33%
Current month-17.91%
1 month-17.91%
3 months-24.17%
6 months-9.54%
Current year-23.52%
More quotes
1 week
0.40
Extreme 0.4016
0.47
1 month
0.38
Extreme 0.3838
0.54
Current year
0.38
Extreme 0.3838
0.75
1 year
0.38
Extreme 0.3838
1.05
3 years
0.38
Extreme 0.3838
4.58
5 years
0.35
Extreme 0.3497
5.56
10 years
0.35
Extreme 0.3497
5.56
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 15-11-30
Director of Finance/CFO - 20-09-30
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 62 15-11-30
Director/Board Member 53 15-11-30
Director/Board Member 65 15-11-30
More insiders
Date Price Change Volume
24-04-29 0.436 +4.88% 1,484,602
24-04-26 0.4157 -0.60% 927,974
24-04-25 0.4182 -3.42% 1,265,709
24-04-24 0.433 +0.70% 1,429,467
24-04-23 0.43 +7.82% 1,657,151

Delayed Quote Nyse, April 29, 2024 at 04:00 pm

More quotes
Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems, Eversense, Eversense XL, and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every five minutes to a mobile app on the user's smartphone. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device. Its CGM system continually and accurately measures a person's glucose levels for up to six months.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
0.436 USD
Average target price
1.633 USD
Spread / Average Target
+274.62%
Consensus